Racura Oncology Ltd RAC
ASX · Australia · Health Technology
AUD 1.86-0.03 (-1.59%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Racura Oncology Limited (ASX: RAC), a clinical-stage biopharmaceutical company developing new small molecule based approaches to cancer treatment, today announced that the first patient has been dosed with RC220 in HARNESS-1, a Phase 1a/b clinical trial evaluating RC220 in combination with osimertinib in patients with epidermal growth factor receptor-mutant (EGFR-mutant) non-small cell lung cancer (NSCLC). The first patient received RC220 at 50 mg/m2 by intravenous infusion. No adverse events we
Racura Oncology, an Australian Phase 3 stage clinical biopharmaceutical company, today announced that the independent Safety Review Committee (SRC) has completed its review of safety data from Cohort 1 of the ongoing CPACS clinical trial, evaluating the safety and pharmacokinetics of RC220 alone and in combination with doxorubicin in advanced metastatic solid tumor patients.
The Australian market is experiencing a rare uptick, with shares set to rise amid ongoing U.S.-Iran negotiations and anticipation of Jim Chalmers' ambitious federal budget. Despite the vintage connotation of "penny stocks," these smaller or newer companies continue to offer intriguing opportunities for growth at lower price points. When backed by solid financials, penny stocks can present a compelling investment case, combining potential value and growth that may be overlooked in larger firms.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.